Yervoy is named as an intervention in 2 current clinical trials in our Ireland, USA and China registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is SWOG Cancer Research Network (1). The most-studied condition is Recurrent Squamous Cell Lung Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)
|
Phase 1 | Recruiting | Shanghai Henlius Biotech | USA, China |
|
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952 · ClinicalTrials.gov ↗ · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
Phase 3 | Active, closed | SWOG Cancer Research Network | Ireland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| SWOG Cancer Research Network | 1 |
| Shanghai Henlius Biotech | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Ireland | 1 | 0 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Ireland, USA and China registers name Yervoy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
SWOG Cancer Research Network (1) and Shanghai Henlius Biotech (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Yervoy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Yervoy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Yervoy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.